Way to go Wake Forest University scientists -- for adding to the body of evidence connecting stress to illness and for reporting before anyone else that the stress hormone epinephrine causes changes in prostate and breast cancer cells that may make them resistant to death.

Emotional stress contributes not only to the development of cancer, says lead researcher George Kulik, D.V.M., Ph.D, but it also reduces the effectiveness of cancer treatments.

Previous research shows levels of epinephrine, produced by the adrenal glands, are sharply increased during stressful situations and can stay elevated during long-term stress and depression.

During this study, published in the on-line Journal of Biological Chemistry, Kulik and colleagues found that a protein called BAD -- the cause of cell death -- becomes inactive when cancer cells are exposed to epinephrine.

This is huge for patients and researchers.

"It may be important for patients who have increased responses to stress to learn to manage the effects," said Kulik. "And, the results point to the possibility of developing an intervention to block the effects of epinephrine."

The Food and Drug Administration (FDA) will take an additional three months to review Wyeth's kidney cancer drug Torisel -- the first of five new medications the company plans to introduce this year.

The FDA needs more time to investigate data on tumor growth in patients taking Torisel. If all goes well, the drug will be one of only three to effectively hold off incurable kidney cancer. The other two drugs are Pfizer's Sutent and Bayer AG's Nexavar.

Robert Ruffolo, president of Wyeth Research, says he is encouraged by the review process so far. And he is optimistic about launching the product in late 2007.

Studies show Torisel, which will cost patients about $30,000 per year, prolonged survival by 50 percent in those faring poorly with kidney cancer. The sickest kidney-cancer patients were essentially kept alive for 10.9 months, compared with 7.3 months with interferon drugs. Torisel also postponed tumor growth for 5.5 months. This is 77 percent longer than with interferon.

Sutent and Nexavar, both on the market since last year, also slow tumor growth. All three kidney-cancer medicines are of the variety that block the growth of cancer cells -- different from standard chemotherapy which kills tumors and harms nearby tissues too.

Wyeth is relatively new to the oncology market. And soon, the company hopes to launch three more cancer drugs. One, called CMC-544, treats non-Hodgkin's lymphoma. Another, SKI-606, is for chronic myelogenous leukemia. And the third, HKI-272, is for breast cancer.

About 51,000 Americans will be diagnosed with kidney cancer this year.

I never would have predicted it -- that a tooth could become a tool for dispensing medication. But the refinement of such a creation is actually in the works and before long, you may be asking not for a gold or decorative tooth but for one capable of doling out your drugs in the exact doses and at the right times.

Think about this:

Researchers from Europe and Israel are working right now on a tiny dispensing system called IntelliDrug. Their goal is to create parts small enough they can fit into a false tooth placed in the back of the mouth. The device will release a specific amount of medication at certain intervals so patients receive the proper dosage right on schedule.

This invention, crafted by an Israeli dentist, could pick up the slack for people who forget to take medicine and could save lives for those whose lives depend on scheduled drug therapy. It could also allow for better absorption of medication into the body.

The IntelliDrug device will deliver medicine directly into the bloodstream through the lining of the cheek around the mouth. Saliva, meanwhile, mixes with the drug and carries it throughout they body in a manner more efficient than just swallowing a pill every few hours.

While researchers hope to one day turn their device into a replacement tooth, the apparatus -- consisting of a stainless steel housing, a pump, custom valves, a microprocessor, batteries, and a reservoir for the drug pill -- currently comes in the form of a block the size of two teeth. It is strapped to the the side of teeth and hugs the inside of the cheek. The unit can be removed, and a technician can refill the drug reservoir, clean the unit, and change batteries when necessary.

Clinical trials on pigs are ongoing. Human testing is expected to begin by the end of the year.

An anti-viral molecule, TBK-1, that the body uses to fight viruses, seems to be vital to the survival of cancer cells. Blocking one enzyme, aldose reductase, was found to stop colon cancer cells in cell culture laboratory tests and in mice implanted with human colon cancer cells, according to University of Texas Southwestern Medical Center researchers.

"We got the surprise that this mechanism is involved in cancer cell survival, even though it's normally involved in immune response," stated Dr. Michael White, associate professor of cell biology at the University of Texas Southwestern Medical Center.

"We found something a little bit different -- an Achilles heel of cancer cells that's apparently broadly conserved among many types of solid tumors. This is making us think that there are many other surprises awaiting discovery regarding biological systems that are inappropriately subverted during development of cancer."

The discovery is called dramatic and could lead to new treatments for colon cancer. If blocking a single anti-viral molecule does shut down the biochemical signals that promote inflammation and colon cancer cell growth, as the researchers are reporting from the results of this study, it will be a dramatic discovery.

Firefighters pull off heroic maneuvers all the time. Heat and smoke and fire are their constant companions. Emergency scenarios keep them perpetually challenged. Risking their lives is a top job responsibility. I can't imagine taking on this line of work, yet I am amazed by those who do -- for their eagerness to save lives while compromising their own. And to read today that cancer is another occupational hazard for firefighters makes me appreciate them even more.

In Edmonton, a firefighter who was praised as a hero for saving the life of a rookie firefighter in 2003 died on Saturday of job-related cancer at the age of 47 -- just two years after doctors diagnosed him with a terminal form of multiple myeloma. Clarke Stevens was expected to live for five years.

Ken Block, president of the Edmonton firefighters union said Stevens' death is a reminder of the risks these heroes take. Block says firefighters are between two and four times more likely to develop certain cancers, and Stevens is the fifth Edmonton firefighter to die of cancer since 2004.

It takes a special person to make saving others' lives a priority. To risk death in so many ways -- for the benefit of strangers -- must be the true definition of selflessness. And thank goodness for these selfless individuals who help keep the rest of us safe.

Sunscreen products containing Mexoryl SX or ecamsule, an ingredient designed to block the sun's harmful UVA rays, have been sold in Canada and Europe for over ten years, but have not been available here.

The Food and Drug Administration (FDA) has recently approved the over-the-counter sale of L'Oreal Anthelios SX sunscreen product containing ecamsule to consumers in the US.

While UVB rays are known to cause sunburn, UVA rays penetrate deeper into the skin and are associated with an increased risk for basal and squamous cell cancers and melanoma skin cancer. Anthelios SX is made by the French cosmetics company L'Oreal. Mexoryl SX is owned by L'Oreal, and is only available in L'Oreal products.

Sunscreens might provide some protection from the harmful rays of the sun, and should be used when going out in the sun. Still your best bet is to shade yourself when spending any length of time in the sun and staying out of the sun during the peak hours of 10 AM to 4 PM when sun can cause the most skin damage.

While Hebrew University of Jerusalem scientists were doing research to increase the size of peaches and nectarines grown on a tree, they discovered a protein with the ability to stop cancer. For example, if you reduce the number of peaches that grow on a peach tree, the fruit that do grow will be bigger in size. Same with the nectarines.

The scientists were researching a protein that inhibits the growth of pollen cells to accomplish the reduction in the number of fruit per tree. When the experiments succeeded, it came to them that the same protein, and the same process, might work in stopping the growth and spread of cancer because the fruit pollen cell works very similar to how a cancer cell works.

According to the university, the scientists used genetic engineering to produce a variant of the protein that shows impressive anti-cancer potential. Not surprisingly, this discovery is said to have caught the attention of the international scientific community and the business community.

In the phenomenal bestseller Foods That Fight Cancer: Preventing Cancer Through Diet, written by Montreal biochemist Richard Beliveau with fellow scientist Denis Gingras, the authors refer to fruits and vegetables as a preventative non-toxic version of chemotherapy.

Originally published in French, the book has recently been translated into English. Based on scientific studies in food chemistry, the book's two main goals are to educate people about what cancer is -- and how to eat for cancer prevention.

Beliveau explains in layman's terms how cancer develops, how it takes years for cancer to develop, how tumors form spontaneously, and how most cancers remain insignificant. He says, "Preventing cancer is destroying these microtumors and blocking them from reaching a stage where they become clinically relevant." There are foods with the biochemical capacity to block some cancers. He wants the reader to realize that we cannot eat as badly as we do and expect medicine to come up with a miracle pill when something goes wrong.

Following is an excerpt of some of the information the reader will find in Foods That Fight Cancer: Preventing Cancer Through Diet:

At the end of March, we told you about nine lawsuits filed in a California court against the makers of five of the most popular sunscreen brands in the U.S. -- Coppertone, Hawaiian Tropic, Banana Boat, Neutrogena and BullFrog -- accusing sunscreen makers of misleading consumers on how well their lotions block the sun's harmful rays, putting millions of people at risk of skin cancer.

Over the weekend, over 166 separate news stories have been filed about these lawsuits. At first I wondered why now, over two months after the news first came out about the lawsuits, suddenly the peaked interest. Are we short on new health news? Maybe.

However, with all the additional coverage, I was able to learn that the accusations might not be a matter of exaggerated claims alone, but a scurrilous attempt to skirt the laws in deliberately misrepresenting the value of sunscreen products for the purpose of profit at the expense of human lives in increased skin cancer risks. Have we just come to a time when we might as well assume that all companies deceive and that our government seems incompetent to protect its citizens? Maybe so.

Here's how this whole situation happened, and why there are now nine lawsuits filed against some of the biggest names in sunblock lotion products. Sunscreen makers claim their sunscreen lotion is waterproof and acts as a sunblock. Years ago, the FDA wanted the claims changed to read water resistant instead of waterproof and sunscreen instead of sunblock. Because the FDA has never imposed the changes, the big name sun lotion makers chose to go with the more descriptive wording that made the lotions sound more effective than they were in actual fact. To some, it might seem a matter of semantics but words have power. The change from sunblock to sunscreen and waterproof to the more accurate water resistant could mean a potential difference in profits. What's at stake? Years of consumer health.

According to what researchers understand when it comes to lung cancer, and it appears there is still more mystery than knowledgeable fact, lung cancer affects men and women differently. Researchers hypothesize this might be due to estrogen and have started a study to determine if estrogen promotes lung cancer in women the same way that estrogen promotes breast cancer. Researchers will be taking a look at the role estrogen plays in the development of lung cancer for women, and if the same drugs used to block estrogen that prevents breast cancer from advancing, or recurring, will work for women with lung cancer.

In a different study, researchers will take an overall look at the biological differences between men and women with lung cancer by identifying what role hormones, genes and other factors play in the development of lung cancer. Like I said, I think there is more scientists don't know than they do know when it comes to lung cancer. But if estrogen does indeed play a role in the development and advancement of lung cancer for women, the drugs that block estrogen from fueling breast cancer are fairly effective and this could add up to real progress for women with lung cancer.